We conducted a test-negative case-control study within the US Veterans Affairs Healthcare System to estimate early vaccine effectiveness (VE) of the BNT162b2 KP.2 vaccine (Pfizer 2024-2025 formulation) against COVID-19 outcomes. Among 44,598 acute respiratory infections between September 5 and November 30, 2024, VE was 68% (42-82%), 57% (46-65%), and 56% (36-69%) against COVID-19-associated hospitalizations, emergency department and urgent care visits, and outpatient visits, respectively. Uptake of updated COVID-19 vaccines remains low.
No takes yet. Share an insight, caveat, or question.
Appaneal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: